- Home
- ACDC vs CRGX Comparison
ACDC vs CRGX Comparison
Compare ACDC & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACDC
- CRGX
- Stock Information
- Founded
- ACDC 2014
- CRGX 2021
- Country
- ACDC United States
- CRGX United States
- Employees
- ACDC N/A
- CRGX N/A
- Industry
- ACDC Oilfield Services/Equipment
- CRGX
- Sector
- ACDC Energy
- CRGX
- Exchange
- ACDC Nasdaq
- CRGX Nasdaq
- Market Cap
- ACDC 1.1B
- CRGX 190.0M
- IPO Year
- ACDC 2022
- CRGX 2023
- Fundamental
- Price
- ACDC $7.44
- CRGX $4.46
- Analyst Decision
- ACDC Hold
- CRGX Hold
- Analyst Count
- ACDC 5
- CRGX 7
- Target Price
- ACDC $7.10
- CRGX $4.67
- AVG Volume (30 Days)
- ACDC 932.3K
- CRGX 502.9K
- Earning Date
- ACDC 08-07-2025
- CRGX 08-11-2025
- Dividend Yield
- ACDC N/A
- CRGX N/A
- EPS Growth
- ACDC N/A
- CRGX N/A
- EPS
- ACDC N/A
- CRGX N/A
- Revenue
- ACDC $2,209,700,000.00
- CRGX N/A
- Revenue This Year
- ACDC N/A
- CRGX $57.81
- Revenue Next Year
- ACDC $0.09
- CRGX N/A
- P/E Ratio
- ACDC N/A
- CRGX N/A
- Revenue Growth
- ACDC N/A
- CRGX N/A
- 52 Week Low
- ACDC $3.83
- CRGX $3.00
- 52 Week High
- ACDC $10.70
- CRGX $25.45
- Technical
- Relative Strength Index (RSI)
- ACDC 43.60
- CRGX 57.89
- Support Level
- ACDC $7.56
- CRGX $4.09
- Resistance Level
- ACDC $8.49
- CRGX $4.51
- Average True Range (ATR)
- ACDC 0.75
- CRGX 0.18
- MACD
- ACDC -0.28
- CRGX 0.00
- Stochastic Oscillator
- ACDC 6.86
- CRGX 77.18
About ACDC ProFrac Holding Corp.
ProFrac Holding Corp is engaged in providing hydraulic fracturing, completion services, and other complementary products and services to upstream oil and gas companies engaged in the exploration and production of North American unconventional oil and natural gas resources. Its operations are focused in West Texas, East Texas/Louisiana, South Texas, Oklahoma, Uinta, and Appalachian. The company operates in three segments: Stimulation Services, Proppant Production, and Manufacturing. Stimulation services, which generate the majority of the revenue for the company operate a fleet of mobile hydraulic fracturing units and other auxiliary equipment that generates revenue by providing stimulation services.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.